{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"by cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.9","upperLimit":"95.5","value":"84.0"}]}],"title":"by cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.0","upperLimit":"99.0","value":"92.0"}]}],"title":"by cycle 66"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Complete Hematological Response (CHR) was defined as\n\n* WBC count \\<10×109/L\n* platelet count \\<450×109/L\n* basophils \\<5%\n* no blasts and promyelocytes in peripheral blood\n* myelocytes+metamyelocytes \\<5% in peripheral blood\n* no evidence of extramedullary disease, including spleen and liver\n* Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"cycle 3, 6, 9, 12, 18, 24, 36, 48, 66","title":"Best Complete Hematological Response (CHR) by Time Point","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}